Dual targeting of vascular endothelial growth factor and bone morphogenetic protein‐9/10 impairs tumor growth through inhibition of angiogenesis

Clinical development of anti‐angiogenic agents has been a major landmark in cancer therapy for several types of cancers. Signals mediated by both vascular endothelial growth factor (VEGF) and bone morphogenetic protein (BMP)‐9 and 10 have been implicated in tumor angiogenesis. However, previous stud...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Sci
Hlavní autoři: Akatsu, Yuichi, Yoshimatsu, Yasuhiro, Tomizawa, Taishi, Takahashi, Kazuki, Katsura, Akihiro, Miyazono, Kohei, Watabe, Tetsuro
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2017
Témata:
Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5276835/
https://ncbi.nlm.nih.gov/pubmed/28133920
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13103
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky